# US 2012/0083478 A1 · Crystalline oxalate salts of a diamide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083478 A1
- Document ID: US20120083478A1
- Status: Published application
- Kind: A1
- Application number: 13/248,840
- Filed: 2011-09-29
- Published: 2012-04-05
- Earliest claimed: 2010-09-30
- Assignees: Theravance, Inc.
- Inventors: Miroslav RAPTA; Venkat THALLADI; Robert S. CHAO
- Web page: https://patentgrep.com/patent/US20120083478A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to crystalline oxalate salts of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-methyl}phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester. This invention also relates to compositions containing such a crystalline oxalate salt; methods of using such a crystalline oxalate salt to, for example, treat a pulmonary disorder; and to processes for preparing such a crystalline oxalate salt.

## Claims

### Claim 1

A crystalline oxalate salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester; wherein the crystalline oxalate salt is selected from:
(a) an isopropanol solvate characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 20 values of 11.66±0.20, 15.75±0.20, 19.55±0.20, 23.00±0.20 and 23.45±0.20; and
(b) a hydrate characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 15.32±0.20, 16.90±0.20, 19.25±0.20 and 23.73±0.20.

### Claim 2 (depends on 1)

The crystalline oxalate salt of claim 1, wherein the crystalline oxalate salt is an isopropanol solvate characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 11.66±0.20, 15.75±0.20, 19.55±0.20, 23.00±0.20 and 23.45±0.20.

### Claim 3 (depends on 2)

The crystalline oxalate salt of claim 2, wherein the crystalline oxalate salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1.

### Claim 4 (depends on 2)

The crystalline oxalate salt of claim 2, wherein the crystalline oxalate salt is characterized by a melting point in the range of about 162° C. to about 164° C.

### Claim 5 (depends on 2)

The crystalline oxalate salt of claim 2, wherein the crystalline oxalate salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 2.

### Claim 6 (depends on 1)

The crystalline oxalate salt of claim 1, wherein the crystalline oxalate salt is a hydrate characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 15.32±0.20, 16.90±0.20, 19.25±0.20 and 23.73±0.20.

### Claim 7 (depends on 6)

The crystalline oxalate salt of claim 6, wherein the crystalline oxalate salt is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 3.

### Claim 8 (depends on 6)

The crystalline oxalate salt of claim 6, wherein the crystalline oxalate salt is characterized by a melting point in the range of about 162° C. to about 164° C.

### Claim 9 (depends on 6)

The crystalline oxalate salt of claim 6, wherein the crystalline oxalate salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 4.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising:
(a) a crystalline oxalate salt of claim 1; and
(b) a pharmaceutically-acceptable carrier.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising:
(a) a crystalline oxalate salt of claim 1;
(b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof; and
(b) a pharmaceutically-acceptable carrier.

### Claim 12 (depends on 1)

A method of treating a pulmonary disorder, the method comprising administering to a patient a crystalline oxalate salt of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pulmonary disorder is chronic obstructive pulmonary disease or asthma.

### Claim 14 (depends on 1)

A method of treating a pulmonary disorder, the method comprising administering to a patient (a) a crystalline oxalate salt of claim 1; and (b) a steroidal anti-inflammatory agent or a pharmaceutically acceptable salt or solvate thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pulmonary disorder is chronic obstructive pulmonary disease or asthma.

### Claim 16 (depends on 1)

A method of producing bronchodilation in a mammal, the method comprising administering a crystalline oxalate salt of claim 1 to the mammal by inhalation.
